KemPharm Inc. (NASDAQ:KMPH)’s share price shot up 5.5% during trading on Wednesday . The stock traded as high as $4.00 and last traded at $4.00, with a volume of 52,083 shares. The stock had previously closed at $3.79.

Several research firms recently commented on KMPH. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of KemPharm in a research report on Saturday, May 14th. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a research report on Saturday, May 14th. Royal Bank Of Canada reissued a “buy” rating on shares of KemPharm in a research report on Sunday, May 8th. Finally, Zacks Investment Research lowered KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $26.80.

The firm’s market cap is $58.57 million. The stock has a 50 day moving average of $4.50 and a 200-day moving average of $11.42.

KemPharm (NASDAQ:KMPH) last posted its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.26. Analysts anticipate that KemPharm Inc. will post ($2.79) earnings per share for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.